Abstract
8524 Background: Ublituximab (UTX) is a novel mAb targeting a unique epitope on the CD20 antigen, glycoengineered for greater ADCC than rituximab (RTX). A prior Phase I/Ib trial with UTX monotherap...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
